Peter Zannikos

1.3k total citations
57 papers, 1.0k citations indexed

About

Peter Zannikos is a scholar working on Pharmacology, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Peter Zannikos has authored 57 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 11 papers in Hematology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Peter Zannikos's work include Pharmacogenetics and Drug Metabolism (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Epilepsy research and treatment (7 papers). Peter Zannikos is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Epilepsy research and treatment (7 papers). Peter Zannikos collaborates with scholars based in United States, Belgium and Germany. Peter Zannikos's co-authors include Juan José Pérez Ruixo, Kim Stuyckens, Arturo Soto-Matos, Gerald Novak, Lawrence S. Brown, Frank M. Balis, Jay Desai, Brigitte C. Widemann, Petrie M. Rainey and Elizabeth Fox and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Peter Zannikos

53 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Zannikos United States 19 215 204 178 170 121 57 1.0k
Christine Alvey United States 22 268 1.2× 259 1.3× 202 1.1× 107 0.6× 110 0.9× 46 1.4k
Markus Jerling Sweden 20 283 1.3× 235 1.2× 205 1.2× 94 0.6× 69 0.6× 44 1.3k
Smiljana Ristič Croatia 19 354 1.6× 197 1.0× 155 0.9× 44 0.3× 136 1.1× 78 1.5k
Kenshi Takechi Japan 19 206 1.0× 158 0.8× 84 0.5× 133 0.8× 89 0.7× 71 900
N. Christophidis Australia 16 201 0.9× 196 1.0× 237 1.3× 82 0.5× 64 0.5× 34 1.1k
C. Puozzo France 23 322 1.5× 689 3.4× 314 1.8× 274 1.6× 242 2.0× 47 1.5k
Gordon Loewen United States 13 381 1.8× 140 0.7× 159 0.9× 49 0.3× 46 0.4× 38 861
Simon Joel United Kingdom 19 652 3.0× 359 1.8× 181 1.0× 95 0.6× 209 1.7× 36 1.7k
Laine J. Murphey United States 24 325 1.5× 104 0.5× 241 1.4× 81 0.5× 222 1.8× 38 1.8k

Countries citing papers authored by Peter Zannikos

Since Specialization
Citations

This map shows the geographic impact of Peter Zannikos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Zannikos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Zannikos more than expected).

Fields of papers citing papers by Peter Zannikos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Zannikos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Zannikos. The network helps show where Peter Zannikos may publish in the future.

Co-authorship network of co-authors of Peter Zannikos

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Zannikos. A scholar is included among the top collaborators of Peter Zannikos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Zannikos. Peter Zannikos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jie, et al.. (2025). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults. Drug Design Development and Therapy. Volume 19. 1503–1514. 1 indexed citations
2.
Moore, Kenneth Todd, et al.. (2023). The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development. The Journal of Clinical Pharmacology. 63(S2). S78–S84. 1 indexed citations
3.
Zimmerman, Brenda, Peter Zannikos, Rajesh Mishra, et al.. (2023). JNJ-10450232 (NTM-006), A novel non-opioid with structural similarities to acetaminophen, produces relatively long-lasting analgesia after a single dose in patients undergoing 3rd molar extraction. Regulatory Toxicology and Pharmacology. 161. 105480–105480. 6 indexed citations
4.
Zannikos, Peter, Bhavna Solanki, Marc De Meulder, et al.. (2023). Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment. Clinical Pharmacokinetics. 62(9). 1315–1328. 1 indexed citations
5.
Willmann, Stefan, Ibrahim Ince, Maurice J. Ahsman, et al.. (2022). Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease. CPT Pharmacometrics & Systems Pharmacology. 11(8). 1111–1121. 6 indexed citations
6.
Rossenu, Stefaan, Peter Zannikos, Partha Nandy, et al.. (2020). Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clinical Pharmacokinetics. 60(4). 501–516. 43 indexed citations
7.
Finkel, Julia C., Ronald Rosenburg, Jay Ariyawansa, et al.. (2019). <p>First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18</p>. Journal of Pain Research. Volume 12. 1925–1936. 14 indexed citations
8.
9.
Meador, Kimford J., H. Robert Brashear, Frank Wiegand, Peter Zannikos, & Gerald Novak. (2011). Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies. Epilepsy & Behavior. 22(2). 324–330. 1 indexed citations
10.
Moore, Kenneth Todd, Peter Zannikos, Bhavna Solanki, et al.. (2011). Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate. The Journal of Clinical Pharmacology. 52(5). 738–746. 1 indexed citations
11.
Jian, Wenying, Richard W. Edom, Naidong Weng, et al.. (2010). Validation and application of an LC–MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. Journal of Chromatography B. 878(20). 1687–1699. 49 indexed citations
12.
Reece, Donna, Dan M. Sullivan, Sagar Lonial, et al.. (2010). Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology. 67(1). 57–67. 94 indexed citations
13.
Mehren, Margaret von, Russell J. Schilder, J. Cheng, et al.. (2008). A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Annals of Oncology. 19(10). 1802–1809. 41 indexed citations
14.
Novak, Gerald, Michael F. Kelley, Peter Zannikos, & Brian D. Klein. (2007). Carisbamate (RWJ-333369). Neurotherapeutics. 4(1). 106–109. 48 indexed citations
15.
Hing, Jeremy, Juan José Pérez Ruixo, Kim Stuyckens, et al.. (2007). Mechanism-based Pharmacokinetic/Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia. Clinical Pharmacology & Therapeutics. 83(1). 130–143. 35 indexed citations
16.
Ruixo, Juan José Pérez, et al.. (2006). Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib. Cancer Chemotherapy and Pharmacology. 58(5). 681–691. 7 indexed citations
17.
Ruixo, Juan José Pérez, et al.. (2006). Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. British Journal of Clinical Pharmacology. 62(1). 81–96. 32 indexed citations
18.
Zannikos, Peter, Bradford K. Jensen, Bruno Boutouyrie, et al.. (2000). Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End‐Stage Renal Insufficiency. The Journal of Clinical Pharmacology. 40(7). 745–751. 3 indexed citations
19.
Zannikos, Peter, et al.. (1999). Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 39(10). 1044–1052. 7 indexed citations
20.
Zannikos, Peter, et al.. (1999). Pharmacokinetics and safety of single IV doses of AMP 579 (RPR 100579) in patients with renal insufficiency. Clinical Pharmacology & Therapeutics. 65(2). 181–181. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine Alvey Breakdown of academic impact, for papers by Markus Jerling Breakdown of academic impact, for papers by Smiljana Ristič Breakdown of academic impact, for papers by Kenshi Takechi Breakdown of academic impact, for papers by N. Christophidis Breakdown of academic impact, for papers by C. Puozzo Breakdown of academic impact, for papers by Gordon Loewen Breakdown of academic impact, for papers by Simon Joel Breakdown of academic impact, for papers by Laine J. Murphey
Rankless by CCL
2026